New weekly shot aims to tame type 2 diabetes

NCT ID NCT07156539

Not yet recruiting Disease control Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 3 study tests an experimental drug called HS-20094 against the standard drug dulaglutide, both given as weekly injections. About 546 adults with type 2 diabetes whose blood sugar is not well controlled on metformin or SGLT2 inhibitors will take part. The main goal is to see how well HS-20094 lowers blood sugar (HbA1c) over 44 weeks, along with effects on weight and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-20094 (an experimental injectable drug) and dulaglutide (a standard injectable diabetes drug)
What this could lead to: If successful, HS-20094 could offer a new weekly injection option for controlling blood sugar and weight in people with type 2 diabetes.
What could go wrong: This is a Phase 3 trial, but HS-20094 is still experimental. It may not prove better or safer than existing treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

Shandong Provincial Hospital

Jinan, Shandong, China
Tianjin Medical University General Hospital (Zhu Xianyi Memorial Hospital)

Tianjin, Tianjn, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.